7/31/25, 11:09 AM DDOTS, Inc.

12 Protocols Found

Current Status Report page.

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.

Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients

Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Reported: 07/31/2025 - 11:09 AM

Sponsor: Children's Oncology Group, Children's Oncology Group - Adolescent and Young Adult Department: Oncology

Status: OPEN

Current Status as of today for:

AGCT1531 NCT03067181

ALTE2131

Multiple Disease Sites

NCT06513962 | Multiple Disease Sites

AGCT1532 NCT02582697 Solid Tumor- Other

Saint Vincent Hospital Cancer Center Green Bay

Protocol	NCT Number	Disease Site	Title
APEC14B1	NCT02402244	Cancer Control-Other	The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
AREN1921	NCT04322318	Kidney (Renal)	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed
			Favorable Histology Wilms Tumors (FHWT)
AREN2231	NCT06401330	Kidney (Renal)	Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
ALTE05N1	NCT00736749	Late Effects	Umbrella Long-Term Follow-Up Protocol
AALL1732	NCT03959085	Leukemia-Acute	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for
		Lymphocytic Leukemia	Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,
		(ALL)	Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
AALL2131	NCT06124157	Leukemia-Acute	An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with
		Lymphocytic Leukemia	Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-
		(ALL)	Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia
AALL2321	NCT06317662	Leukemia-Acute	A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly
		Lymphocytic Leukemia	Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged
		(ALL)	Patients to Addition of Venetoclax
AAML1831	NCT04293562	Leukemia-Acute	A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy
		Myelogenic Leukemia	Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3
		(AML)	Inhibitor Gilteritinib for Patients with FLT3 Mutations
AHOD2131	NCT05675410	Lymphoma-Hodgkin's	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with
			Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II
			Classic Hodgkin Lymphoma

with Intermediate and Poor-Risk Germ Cell Tumors